Clinical Trial Update: A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) [Phase 2]

View source ↗

Summary

Phase 2 study of ripretinib (DCC-2618) in patients with advanced gastrointestinal stromal tumors has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Ripretinib (ripretinib)

Snippet

Sponsor: Zai Lab (Shanghai) Co., Ltd. | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED | Results posted: 2025-03-03